Accessibility Menu
Eisai logo

Eisai(OTC) ESALF

Market Cap$8.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+64%
5 Year-57%
1 Year+12%
1 Month+13%
$31.00
-3.13%
-1.00Today
Eisai last closing stock price
MetricPriceDate
Last closeUSD 31.002026-09-02
Eisai stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.13%USD 32.002026-08-26
1 month+12.56%USD 27.542026-07-31
3 month+29.82%USD 23.882026-06-04
Year to date+6.07%USD 29.232025-12-31
1 year+12.39%USD 27.582025-09-02
3 year-46.61%USD 58.062023-09-01
5 year-57.46%USD 72.882021-09-03
Since inception+63.94%USD 18.912003-07-17

Eisai Financials at a Glance

Market Cap

$8.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥859.67B

Net Income (TTM)

¥42.33B

EPS (TTM)

$0.97

P/E Ratio

31.89

Dividend

$1.04

Beta (Volatility)

0.08 (Low)

Price

$31.00

Volume

1

Open

$31.00

Previous Close

$31.00

Daily Range

$31.00 - $31.00

52-Week Range

$23.88 - $35.83

Estimated Earnings Date

Nov 10, 2026

ESALF News

Scale

FDA Asks That Weight Loss Drug Belviq Be Pulled From the Market

Brian Orelli, PhDFeb 13, 2020
AD

Why Biogen Stock Is Crashing Today

George Budwell, PhDMar 21, 2019
Alz

Why Biogen's Stock Is Slumping Today

George Budwell, PhDJul 26, 2018

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eisai

Eisai Co., Ltd. is a pharmaceutical company based in Tokyo, Japan, specializing in the development and marketing of a diverse range of medicinal products. The company focuses on neurological conditions and oncology, providing innovative treatments that address significant health challenges.

Products and Services
  • Aricept for Alzheimer's disease and dementia
  • Lenvima, a targeted therapy for various cancers
  • Consumer health products like Chocola BB Plus
Growth Outlook
  • Revenue increased to JPY 232.6 billion in Q1 2026
  • Net income rose to JPY 18.1 billion in Q1 2026
  • Strong demand for oncology products supports future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of JPY 1.1 trillion
  • Net profit margin of 4.9% reflects operational efficiency
  • Dividend yield of 3.31% indicates shareholder return commitment
Eisai Co., Ltd. has established itself as a key player in the pharmaceutical industry, particularly in the treatment of neurological disorders and cancer. The company's flagship products, such as Aricept and Lenvima, have garnered significant market share, contributing to a robust revenue stream. Recent financial performance shows a positive trend, with a notable increase in revenue and net income in the latest quarter, indicating strong operational capabilities and market demand. The growth outlook remains promising, driven by the increasing prevalence of neurological conditions and cancer, which are expected to boost sales of Eisai's innovative therapies. The company's commitment to research and development further enhances its potential for future growth, as it continues to explore new treatment options. Financially, Eisai demonstrates solid performance metrics, with a TTM revenue of JPY 1.1 trillion and a net profit margin of 4.9%. The dividend yield of 3.31% reflects a commitment to returning value to shareholders, making it an attractive option for investors seeking exposure to the healthcare sector. Overall, Eisai Co., Ltd. presents a compelling investment opportunity within the pharmaceutical landscape.
AI Generated • Aug 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,543

CEO

Haruo Naito

Website

www.eisai.co.jp

Headquarters

Tokyo, TY 112-8088, JP

ESALF Financials

Key Financial Metrics (TTM)

Gross Margin

76.70%

Operating Margin

5.11%

Net Income Margin

4.94%

Return on Equity

4.77%

Return on Capital

3.71%

Return on Assets

2.72%

Earnings Yield

3.14%

Dividend Yield

3.37%

Payout Ratio

1.07%

Stock Overview

Market Cap

$8.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

282.46M

Volume

1

Avg. Volume

244.484

Financials (TTM)

Gross Profit

¥659.30B

Operating Income

¥43.75B

EBITDA

¥93.47B

Operating Cash Flow

¥58.02B

Capital Expenditure

-¥15.12B

Free Cash Flow

¥42.90B

Cash & ST Invst.

¥309.48B

Total Debt

¥269.38B

Eisai Performance Analysis

Eisai annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 5,495,248,038-18.3%
20242024-03-31JPY 5,136,302,320-6.5%
20252025-03-31JPY 5,178,078,7190.8%
20262026-03-31JPY 5,477,248,5255.8%
Eisai sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-1.7%
Q32025-12-3110.0%
Q42026-03-31-6.1%
Q12026-06-3012.5%
Eisai annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 1.43-4.1%
20242024-03-31JPY 1.02-28.3%
20252025-03-31JPY 1.074.9%
20262026-03-31JPY 0.91-15.5%
Eisai sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-29.8%
Q32025-12-3166.9%
Q42026-03-31-119.0%
Q12026-06-30656.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

¥232.64B

+14.2%

Gross Profit

¥181.92B

+13.1%

Gross Margin

78.20%

N/A

Market Cap

$8.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$830.53K

N/A

Employees

10,543

N/A

Net Income

¥18.11B

+24.5%

EBITDA

¥33.87B

+2.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

¥309.48B

+8.4%

Total Debt

¥269.38B

+12.7%

Accounts Receivable

¥251.29B

+14.2%

Inventory

¥279.97B

+23.2%

Long Term Debt

¥183.27B

+83.6%

Short Term Debt

¥86.11B

-38.1%

Return on Assets

2.72%

N/A

Return on Invested Capital

3.76%

N/A

Free Cash Flow

-¥6.80B

-96.6%

Operating Cash Flow

-¥2.57B

-333.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KYKOFKyowa Kirin Co., Ltd.
$15.80+9.53%
WILLFDemant A/S
$44.03+0.00%
GIFLFGrifols, S.A.
$11.76+0.00%
WILYYDemant A/S
$22.70+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About ESALF

What is the current price of Eisai?

Eisai is trading at $31.00 per share.

What is the 52-week range for Eisai?

Over the past 52 weeks, Eisai has traded between $23.88 and $35.83.

How much debt does Eisai have?

As of the most recent reporting period, Eisai reported total debt of ¥1.67B.

How much cash does Eisai have on hand?

Eisai reported ¥1.92B in cash and cash equivalents in its most recent financial results.

What is Eisai’s dividend yield?

Eisai currently has a dividend yield of 3.37%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services